CDK4 and breast carcinoma: Abemaciclib (Figure 1), the newest benzimidazole–pyrimidine hybrid CDK4/6 inhibitor for the treatment of certain types of breast cancer, approved in 2017, is the drug that demonstrates the efficacy of the presence of the two heterocyclic rings in its structure [51,52,53,54].